BA
BIVV

Boston Advisors’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Boston Advisors’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-15,359
Closed -$877K – 688
2017
Q3 		$877K Buy
+15,359
New +$900K 0.02% 383

Other funds holding BIVV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JIM
Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

Boston Advisors's BIVV Position: Q4 2017 in Review

Boston Advisors sold out of Bioverativ Inc. Common Stock (BIVV) in Q4 2017, closing a stake of 15,359 shares — an estimated $877K sold.

Boston Advisors first reported a position in BIVV in Q3 2017 and held it in 1 quarter. The position peaked at $877K in Q3 2017. 459 funds tracked by Wall St. Rank hold BIVV as of Q4 2017.

  • Boston Advisors reported no remaining Bioverativ Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Boston Advisors sold 15,359 Bioverativ Inc. Common Stock shares in Q4 2017, an estimated $877K.
  • Boston Advisors first reported a position in Bioverativ Inc. Common Stock in Q3 2017 and held it in 1 quarter.
  • Boston Advisors's Bioverativ Inc. Common Stock position peaked at $877K in Q3 2017.
  • 459 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q4 2017.

Based on Boston Advisors's 13F filing for Q4 2017, filed 24 Jan 2018.